1
|
Aghakhanyan G, Rullmann M, Rumpf J, Schroeter ML, Scherlach C, Patt M, Brendel M, Koglin N, Stephens AW, Classen J, Hoffmann KT, Sabri O, Barthel H. Interplay of tau and functional network connectivity in progressive supranuclear palsy: a [ 18F]PI-2620 PET/MRI study. Eur J Nucl Med Mol Imaging 2022; 50:103-114. [PMID: 36048259 DOI: 10.1007/s00259-022-05952-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Accepted: 08/23/2022] [Indexed: 01/18/2023]
Abstract
PURPOSE Progressive supranuclear palsy (PSP) is primary 4-repeat tauopathy. Evidence spanning from imaging studies indicate aberrant connectivity in PSPs. Our goal was to assess functional connectivity network alterations in PSP patients and the potential link between regional tau-burden and network-level functional connectivity using the next-generation tau PET tracer [18F]PI-2620 and resting-state functional MRI (fMRI). MATERIAL AND METHODS Twenty-four probable PSP patients (70.9 ± 6.9 years, 13 female), including 14 Richardson syndrome (RS) and 10 non-RS phenotypes, underwent [18F]PI-2620 PET/MRI imaging. Distribution volume ratios (DVRs) were estimated using non-invasive pharmacokinetic modeling. Resting-state fMRI was also acquired in these patients as well as in thirteen older non-AD MCI reference group (64 ± 9 years, 4 female). The functional network was constructed using 141 by 141 region-to-region functional connectivity metrics (RRC) and network-based statistic was carried out (connection threshold p < 0.001, cluster threshold pFDR < 0.05). RESULTS In total, 9870 functional connections were analyzed. PSPs compared to aged non-AD MCI reference group expressed aberrant connectivity evidenced by the significant NBS network consisting of 89 ROIs and 118 connections among them (NBS mass 4226, pFDR < 0.05). Tau load in the right globus pallidus externus (GPe) and left dentate nucleus (DN) showed significant effects on functional network connectivity. The network linked with increased tau load in the right GPe was associated with hyperconnectivity of low-range intra-opercular connections (NBS mass 356, pFDR < 0.05), while the network linked with increased tau load in the left cerebellar DN was associated with cerebellar hyperconnectivity and cortico-cerebellar hypoconnectivity (NBS mass 517, pFDR < 0.05). CONCLUSIONS PSP patients show altered functional connectivity. Network incorporating deep gray matter structures demonstrate hypoconnectivity, cerebellum hyperconnectivity, while cortico-cortical connections show variable changes. Tau load in the right GPe and left DN is associated with functional networks which strengthen low-scale intra-opercular and intra-cerebellar connections and weaken opercular-cerebellar connections. These findings support the concept of tau load-dependent functional network changes in PSP, by that providing evidence for downstream effects of neuropathology on brain functionality in this primary tauopathy.
Collapse
Affiliation(s)
- Gayane Aghakhanyan
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany. .,Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, Italy.
| | - M Rullmann
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - J Rumpf
- Department of Neurology, University of Leipzig, Leipzig, Germany
| | - M L Schroeter
- Max Planck Institute for Human Cognitive and Brain Sciences & Clinic for Cognitive Neurology, University of Leipzig, Leipzig, Germany
| | - C Scherlach
- Department of Neuroradiology, University of Leipzig, Leipzig, Germany
| | - M Patt
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - M Brendel
- Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany
| | - N Koglin
- Life Molecular Imaging GmbH, Berlin, Germany
| | | | - J Classen
- Department of Neurology, University of Leipzig, Leipzig, Germany
| | - K T Hoffmann
- Department of Neuroradiology, University of Leipzig, Leipzig, Germany
| | - O Sabri
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - H Barthel
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| |
Collapse
|
2
|
Barthel H, Darne C, Gaté L, Visvikis A, Seidel C. MWCNTs induced epithelio-mesenchymal transition of BEAS-2B cells. Toxicol Lett 2021. [DOI: 10.1016/s0378-4274(21)00595-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
3
|
Siamwala JH, Zhao A, Barthel H, Pagano FS, Gilbert RJ, Rounds S. Adaptive and innate immune mechanisms in cardiac fibrosis complicating pulmonary arterial hypertension. Physiol Rep 2020; 8:e14532. [PMID: 32786064 PMCID: PMC7422804 DOI: 10.14814/phy2.14532] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Revised: 07/03/2020] [Accepted: 07/06/2020] [Indexed: 12/24/2022] Open
Abstract
Pulmonary arterial hypertension (PAH) is a syndrome diagnosed by increased mean pulmonary artery (PA) pressure and resistance and normal pulmonary capillary wedge pressure. PAH is characterized pathologically by distal pulmonary artery remodeling, increased pulmonary vascular resistance, and plexiform lesions (PLs). Right ventricular fibrosis and hypertrophy, leading to right ventricular failure, are the main determinants of mortality in PAH. Recent work suggests that right ventricular fibrosis results from resident cardiac fibroblast activation and conversion to myofibroblasts, leading to replacement of contractile cardiomyocytes with nondistensible tissue incapable of conductivity or contractility. However, the origins, triggers, and consequences of myofibroblast expansion and its pathophysiological relationship with PAH are unclear. Recent advances indicate that signals generated by adaptive and innate immune cells may play a role in right ventricular fibrosis and remodeling. This review summarizes recent insights into the mechanisms by which adaptive and innate immune signals participate in the transition of cardiac fibroblasts to activated myofibroblasts and highlights the existing gaps of knowledge as relates to the development of right ventricular fibrosis.
Collapse
Affiliation(s)
- Jamila H. Siamwala
- Department of Molecular PharmacologyPhysiology and BiotechnologyBrown UniversityProvidenceRIUSA
- Warren Alpert Medical School of Brown UniversityProvidence VA Medical CenterProvidenceRIUSA
| | - Alexander Zhao
- Department of Molecular PharmacologyPhysiology and BiotechnologyBrown UniversityProvidenceRIUSA
| | - Haley Barthel
- Department of Molecular PharmacologyPhysiology and BiotechnologyBrown UniversityProvidenceRIUSA
| | - Francesco S. Pagano
- Department of Molecular PharmacologyPhysiology and BiotechnologyBrown UniversityProvidenceRIUSA
| | - Richard J. Gilbert
- Ocean State Research InstituteProvidence VA Medical CenterProvidenceRIUSA
| | - Sharon Rounds
- Warren Alpert Medical School of Brown UniversityProvidence VA Medical CenterProvidenceRIUSA
- Department of MedicineDivision of PulmonaryCritical Care and SleepWarren Alpert Medical School of Brown UniversityProvidenceRIUSA
| |
Collapse
|
4
|
McGuire D, Lane N, Segal N, Metyas S, Barthel H, Miller M, Rosen D, Kumagai Y. TPX-100 leads to marked, sustained improvements in subjects with knee osteoarthritis: pre-clinical rationale and results of a controlled clinical trial. Osteoarthritis Cartilage 2018. [DOI: 10.1016/j.joca.2018.02.502] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
|
5
|
Kämpfer I, Seese A, Dannenberg C, Kluge R, Burchert W, Knapp WH, Barthel H. Improvement of Brain SPECT by Stabilization of Tc-99m-HMPAO with Methylene Blue or Cobalt Chloride. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1632196] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Summary
Aim: This present study was carried out to investigate whether stabilization of Tc-99m-HMPAO with methylene blue (MB) or cobalt chloride (CC) causes a sensible improvement in image quality and how cerebral to noncerebral activity ratios compare with those of Tc-99m-ECD. Methods: 30 minutes after preparation 400-600 MBq unstabilized Tc-99m-HMPAO (N = 35 patients), Tc-99m-HMPAO added with MB (N = 24 patients), added with CC (N = 30 patients) or Tc-99m-ECD (N = 28 patients) were injected. Radiochemical stability was measured in vitro with three chromatographical methods. Image quality was assessed quantitatively using two ratios, one of them determined by count densities of brain/scalp (QS), the other one by count densities of brain/ nose (QN). In addition, image quality (0 = bad, 3 = excellent) and background activity (0 = high, 3 = no) were visually assessed by three independent observers. Results: In contrast to unstabilized Tc-99m-HMPAO the integrity of the complexes of MB-Tc-99m-HMPAO, CC-Tc-99m-HMPAO and Tc-99m-ECD decreased only by a few percent during a period of 2 hours after reconstitution (66.8 ± 9.9 vs. 93.0 ± 2.5, 91.8 ± 1.9 and 96.9 ± 1.4%, p <0.001). Qs and Qn (m.v. ± SD) differed significantly between studies using unstabilized Tc-99m-HMPAO (3.0 ± 0.4 and 2.1 ± 0.3), MB-Tc-99m-HMPAO (3.4 ± 0.4 and 2.3 ± 0.3), CC-Tc-99m-H M PAO (3.6 ± 0.6 and 2.6 ± 0.4) and those using Tc-99m-ECD (4.3 ± 0.7 and 4.8 ± 1.4; p <0.05 and <0.001). Stabilization with CC or MB resulted in significant higher scoring of image quality and lower scoring of background activity in comparison to that of unstabilized Tc-99m-HMPAO, without reaching the scores obtained with Tc-99m-ECD. Conclusions: It is concluded that stabilization of Tc-99m-HMPAO with MB or CC definitely improves image quality in rCBF-SPECT, without reaching that of Tc-99m-ECD. Improvement of image quality results from the reduction of the amount of decomposition products that contribute to considerable extracerebral activity.
Collapse
|
6
|
Bailey DL, Pichler BJ, Gückel B, Antoch G, Barthel H, Bhujwalla ZM, Biskup S, Biswal S, Bitzer M, Boellaard R, Braren RF, Brendle C, Brindle K, Chiti A, la Fougère C, Gillies R, Goh V, Goyen M, Hacker M, Heukamp L, Knudsen GM, Krackhardt AM, Law I, Morris JC, Nikolaou K, Nuyts J, Ordonez AA, Pantel K, Quick HH, Riklund K, Sabri O, Sattler B, Troost EGC, Zaiss M, Zender L, Beyer T. Combined PET/MRI: Global Warming-Summary Report of the 6th International Workshop on PET/MRI, March 27-29, 2017, Tübingen, Germany. Mol Imaging Biol 2018; 20:4-20. [PMID: 28971346 PMCID: PMC5775351 DOI: 10.1007/s11307-017-1123-5] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
The 6th annual meeting to address key issues in positron emission tomography (PET)/magnetic resonance imaging (MRI) was held again in Tübingen, Germany, from March 27 to 29, 2017. Over three days of invited plenary lectures, round table discussions and dialogue board deliberations, participants critically assessed the current state of PET/MRI, both clinically and as a research tool, and attempted to chart future directions. The meeting addressed the use of PET/MRI and workflows in oncology, neurosciences, infection, inflammation and chronic pain syndromes, as well as deeper discussions about how best to characterise the tumour microenvironment, optimise the complementary information available from PET and MRI, and how advanced data mining and bioinformatics, as well as information from liquid biomarkers (circulating tumour cells and nucleic acids) and pathology, can be integrated to give a more complete characterisation of disease phenotype. Some issues that have dominated previous meetings, such as the accuracy of MR-based attenuation correction (AC) of the PET scan, were finally put to rest as having been adequately addressed for the majority of clinical situations. Likewise, the ability to standardise PET systems for use in multicentre trials was confirmed, thus removing a perceived barrier to larger clinical imaging trials. The meeting openly questioned whether PET/MRI should, in all cases, be used as a whole-body imaging modality or whether in many circumstances it would best be employed to give an in-depth study of previously identified disease in a single organ or region. The meeting concluded that there is still much work to be done in the integration of data from different fields and in developing a common language for all stakeholders involved. In addition, the participants advocated joint training and education for individuals who engage in routine PET/MRI. It was agreed that PET/MRI can enhance our understanding of normal and disrupted biology, and we are in a position to describe the in vivo nature of disease processes, metabolism, evolution of cancer and the monitoring of response to pharmacological interventions and therapies. As such, PET/MRI is a key to advancing medicine and patient care.
Collapse
Affiliation(s)
- D L Bailey
- Department of Nuclear Medicine, Royal North Shore Hospital, and Faculty of Health Sciences, University of Sydney, Sydney, Australia
| | - B J Pichler
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard-Karls-Universität, Tübingen, Germany
| | - B Gückel
- Department of Diagnostic and Interventional Radiology, University of Tübingen, Tübingen, Germany
| | - G Antoch
- Department of Diagnostic and Interventional Radiology, Medical Faculty, University Dusseldorf, 40225, Dusseldorf, Germany
| | - H Barthel
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - Z M Bhujwalla
- Division of Cancer Imaging Research, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA
| | - S Biskup
- Praxis für Humangenetik Tübingen, Paul-Ehrlich-Str. 23, 72076, Tübingen, Germany
| | - S Biswal
- Molecular Imaging Program at Stanford (MIPS) and Bio-X, Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA
| | - M Bitzer
- Department of Internal Medicine I, Eberhard-Karls University, Tübingen, Germany
| | - R Boellaard
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - R F Braren
- Institute of Diagnostic and Interventional Radiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - C Brendle
- Diagnostic and Interventional Neuroradiology, Department of Radiology, Eberhard Karls University, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany
| | - K Brindle
- Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK
- Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge, CB2 1GA, UK
| | - A Chiti
- Department of Biomedical Sciences, Humanitas University, Milan, Italy
- Department of Nuclear Medicine, Humanitas Research Hospital, Milan, Italy
| | - C la Fougère
- Department of Radiology, Nuclear Medicine and Clinical Molecular Imaging, Eberhard-Karls-Universität, Tübingen, Germany
| | - R Gillies
- Department of Cancer Imaging and Metabolism, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33621, USA
| | - V Goh
- Cancer Imaging, School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK
- Department of Radiology, Guy's & St Thomas' Hospitals London, London, UK
| | - M Goyen
- GE Healthcare GmbH, Beethovenstrasse 239, Solingen, Germany
| | - M Hacker
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
| | | | - G M Knudsen
- Neurobiology Research Unit, Rigshospitalet and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - A M Krackhardt
- III. Medical Department, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - I Law
- Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - J C Morris
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO, USA
| | - K Nikolaou
- Department of Diagnostic and Interventional Radiology, University of Tübingen, Tübingen, Germany
| | - J Nuyts
- Nuclear Medicine & Molecular Imaging, KU Leuven, Leuven, Belgium
| | - A A Ordonez
- Department of Pediatrics, Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - K Pantel
- Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - H H Quick
- High Field and Hybrid MR Imaging, University Hospital Essen, Essen, Germany
- Erwin L. Hahn Institute for MR Imaging, University of Duisburg-Essen, Essen, Germany
| | - K Riklund
- Department of Radiation Sciences, Umea University, Umea, Sweden
| | - O Sabri
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - B Sattler
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - E G C Troost
- OncoRay-National Center for Radiation Research in Oncology, Dresden, Germany
- Institute of Radiooncology-OncoRay, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
- Department of Radiotherapy, University Hospital Carl Gustav Carus and Medical Faculty of Technische Universität Dresden, Dresden, Germany
- German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany
| | - M Zaiss
- High Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tübingen, Germany
| | - L Zender
- Department of Internal Medicine VIII, University Hospital Tübingen, Tübingen, Germany
| | - Thomas Beyer
- QIMP Group, Center for Medical Physics and Biomedical Engineering General Hospital Vienna, Medical University Vienna, 4L, Waehringer Guertel 18-20, 1090, Vienna, Austria.
| |
Collapse
|
7
|
Lücke C, Oppolzer B, Werner P, Foldyna B, Lurz P, Jochimsen T, Brenneis B, Lehmkuhl L, Sattler B, Grothoff M, Barthel H, Sabri O, Gutberlet M. Comparison of volumetric and functional parameters in simultaneous cardiac PET/MR: feasibility of volumetric assessment with residual activity from prior PET/CT. Eur Radiol 2017; 27:5146-5157. [PMID: 28631080 PMCID: PMC5674117 DOI: 10.1007/s00330-017-4896-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2016] [Revised: 04/24/2017] [Accepted: 05/12/2017] [Indexed: 11/03/2022]
Abstract
OBJECTIVE To compare cardiac left ventricular (LV) parameters in simultaneously acquired hybrid fluorine-18-fluorodeoxyglucose ([18F] FDG) positron emission tomography/magnetic resonance imaging (PET/MRI) in patients with residual tracer activity of upstream PET/CT. METHODS Twenty-nine patients (23 men, age 58±17 years) underwent cardiac PET/MRI either directly after a non-cardiac PET/CT with homogenous cardiac [18F] FDG uptake (n=20) or for viability assessment (n=9). Gated cardiac [18F] FDG PET and cine MR sequences were acquired simultaneously and evaluated blinded to the cross-imaging results. Image quality (IQ), end-diastolic (LVEDV), end-systolic volume (LVESV), ejection fraction (LVEF) and myocardial mass (LVMM) were measured. Pearson correlation and intraclass correlation coefficient (ICC), regression and a Bland-Altman analysis were assessed. RESULTS Except LVMM, volumetric and functional LV parameters demonstrated high correlations (LVESV: r=0.97, LVEDV: r=0.95, LVEF: r=0.91, LVMM: r=0.87, each p<0.05), but wide limits of agreement (LOA) for LVEDV (-25.3-82.5ml); LVESV (-33.1-72.7ml); LVEF (-18.9-14.8%) and LVMM (-78.2-43.2g). Intra- and interobserver reliability were very high (ICC≥0.95) for all parameters, except for MR-LVEF (ICC=0.87). PET-IQ (0-3) was high (mean: 2.2±0.9) with significant influence on LVMM calculations only. CONCLUSION In simultaneously acquired cardiac PET/MRI data, LVEDV, LVESV and LVEF show good agreement. However, the agreement seems to be limited if cardiac PET/MRI follows PET/CT and only the residual activity is used. KEY POINTS • [ 18 F] FDG PET-MRI is feasible with residual [ 18 F] FDG activity in patients with homogenous cardiac uptake. • Cardiac volumes and function assessed by PET/MRI show good agreement. • LVEDV and LVESV are underestimated; PET overestimates LVMM and LVEF. • Cardiac PET and MRI data correlate better when acquired simultaneously than sequentially. • PET and MRI should not assess LV parameters interchangeably.
Collapse
Affiliation(s)
- C Lücke
- Department of Diagnostic and Interventional Radiology, University Leipzig - Heart Center, Strümpellstr. 39, 04289, Leipzig, Germany.
| | - B Oppolzer
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - P Werner
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - B Foldyna
- Department of Diagnostic and Interventional Radiology, University Leipzig - Heart Center, Strümpellstr. 39, 04289, Leipzig, Germany
- Cardiac MR PET CT Program, Massachusetts General Hospital - Harvard Medical School, Boston, MA, USA
| | - P Lurz
- Clinic for Internal Medicine/Cardiology, University Leipzig - Heart Center, Leipzig, Germany
| | - T Jochimsen
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - B Brenneis
- Department of Diagnostic and Interventional Radiology, University Leipzig - Heart Center, Strümpellstr. 39, 04289, Leipzig, Germany
| | - L Lehmkuhl
- Radiologische Klinik, Herz- und Gefäß-Klinik GmbH, Bad Neustadt, Germany
| | - B Sattler
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - M Grothoff
- Department of Diagnostic and Interventional Radiology, University Leipzig - Heart Center, Strümpellstr. 39, 04289, Leipzig, Germany
| | - H Barthel
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - O Sabri
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - M Gutberlet
- Department of Diagnostic and Interventional Radiology, University Leipzig - Heart Center, Strümpellstr. 39, 04289, Leipzig, Germany
| |
Collapse
|
8
|
Schönecker S, Prix C, Raiser T, Ackl N, Wlasich E, Stenglein-Krapf G, Mille E, Brendel M, Sabri O, Patt M, Barthel H, Bartenstein P, Levin J, Rominger A, Danek A. [Amyloid positron-emission-tomography with [ 18 F]-florbetaben in the diagnostic workup of dementia patients]. Nervenarzt 2017; 88:156-161. [PMID: 27913818 DOI: 10.1007/s00115-016-0249-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND To this day the definite diagnosis of Alzheimer's disease still relies on post-mortem histopathological detection of neurofibrillary tangles and beta-amyloid deposits. Amyloid positron emission tomography (PET) is a new diagnostic tool that enables the in vivo quantification of pathological beta-amyloid deposits. The aim of the current study was to evaluate to what extent 18F-florbetaben-PET (FBB-PET) influences the diagnosis of patients with dementia. MATERIAL AND METHODS Imaging with FBB-PET was performed on 33 patients from our outpatient department for cognitive neurology. Beforehand all patients underwent a comprehensive clinical, neuropsychiatric and laboratory examination as well as imaging by means of magnetic resonance imaging (MRI) and fluorodeoxyglucose-PET. The working diagnoses before and after FBB-PET imaging were compared. RESULTS 17 out of 33 patients were scored as FBB-PET positive. In four cases the initial diagnosis had to be changed to Alzheimer's disease (three cases) and cerebral amyloid angiopathy (one case) due to the positive FBB-PET scan. 16 patients showed a negative FBB-PET scan. In three patients the initial diagnosis of Alzheimer's disease could be ruled out due to the negative FBB-PET scan. Overall, in 7 out of 33 examined patients the initial diagnosis had to be changed because of the findings of the FBB-PET scan. In 24 patients the initial diagnosis was confirmed by the results of the FBB-PET scan. CONCLUSION Amyloid-PET is currently no standard procedure in the diagnosis of dementia; however, it can be a helpful additional diagnostic tool when used according to the "Appropriate Use Criteria" and the S3 guidelines on dementia in cases of unclear clinical presentation, atypically early age of onset as well as in patients with persistent or progressive unexplained mild cognitive impairment. By facilitating early diagnosis amyloid-PET imaging allows patient selection for therapeutic drug trials.
Collapse
Affiliation(s)
- S Schönecker
- Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, München, Deutschland.
| | - C Prix
- Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, München, Deutschland
| | - T Raiser
- Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), München, Deutschland
| | - N Ackl
- Memory Clinic, Psychiatrische Dienste Thurgau, Münsterlingen, Schweiz
| | - E Wlasich
- Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, München, Deutschland
| | - G Stenglein-Krapf
- Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, München, Deutschland
| | - E Mille
- Klinik und Poliklinik für Nuklearmedizin, Ludwig-Maximilians-Universität, München, Deutschland
| | - M Brendel
- Klinik und Poliklinik für Nuklearmedizin, Ludwig-Maximilians-Universität, München, Deutschland
| | - O Sabri
- Klinik und Poliklinik für Nuklearmedizin, Universität Leipzig, Leipzig, Deutschland
| | - M Patt
- Klinik und Poliklinik für Nuklearmedizin, Universität Leipzig, Leipzig, Deutschland
| | - H Barthel
- Klinik und Poliklinik für Nuklearmedizin, Universität Leipzig, Leipzig, Deutschland
| | - P Bartenstein
- Klinik und Poliklinik für Nuklearmedizin, Ludwig-Maximilians-Universität, München, Deutschland.,Munich Cluster Syst Neurol SyNergy, München, Deutschland
| | - J Levin
- Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, München, Deutschland.,Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), München, Deutschland
| | - A Rominger
- Klinik und Poliklinik für Nuklearmedizin, Ludwig-Maximilians-Universität, München, Deutschland.,Munich Cluster Syst Neurol SyNergy, München, Deutschland
| | - A Danek
- Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, München, Deutschland
| |
Collapse
|
9
|
Bailey DL, Pichler BJ, Gückel B, Barthel H, Beer AJ, Botnar R, Gillies R, Goh V, Gotthardt M, Hicks RJ, Lanzenberger R, la Fougere C, Lentschig M, Nekolla SG, Niederdraenk T, Nikolaou K, Nuyts J, Olego D, Riklund KÅ, Signore A, Schäfers M, Sossi V, Suminski M, Veit-Haibach P, Umutlu L, Wissmeyer M, Beyer T. Combined PET/MRI: from Status Quo to Status Go. Summary Report of the Fifth International Workshop on PET/MR Imaging; February 15-19, 2016; Tübingen, Germany. Mol Imaging Biol 2016; 18:637-50. [PMID: 27534971 PMCID: PMC5010606 DOI: 10.1007/s11307-016-0993-2] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
This article provides a collaborative perspective of the discussions and conclusions from the fifth international workshop of combined positron emission tomorgraphy (PET)/magnetic resonance imaging (MRI) that was held in Tübingen, Germany, from February 15 to 19, 2016. Specifically, we summarise the second part of the workshop made up of invited presentations from active researchers in the field of PET/MRI and associated fields augmented by round table discussions and dialogue boards with specific topics. This year, this included practical advice as to possible approaches to moving PET/MRI into clinical routine, the use of PET/MRI in brain receptor imaging, in assessing cardiovascular diseases, cancer, infection, and inflammatory diseases. To address perceived challenges still remaining to innovatively integrate PET and MRI system technologies, a dedicated round table session brought together key representatives from industry and academia who were engaged with either the conceptualisation or early adoption of hybrid PET/MRI systems. Discussions during the workshop highlighted that emerging unique applications of PET/MRI such as the ability to provide multi-parametric quantitative and visual information which will enable not only overall disease detection but also disease characterisation would eventually be regarded as compelling arguments for the adoption of PET/MR. However, as indicated by previous workshops, evidence in favour of this observation is only growing slowly, mainly due to the ongoing inability to pool data cohorts from independent trials as well as different systems and sites. The participants emphasised that moving from status quo to status go entails the need to adopt standardised imaging procedures and the readiness to act together prospectively across multiple PET/MRI sites and vendors.
Collapse
Affiliation(s)
- D L Bailey
- Department of Nuclear Medicine, Royal North Shore Hospital, and Faculty of Health Sciences, University of Sydney, Sydney, Australia
| | - B J Pichler
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard-Karls-Universität, Tübingen, Germany
| | - B Gückel
- Department of Interventional and Diagnostic Radiology, Eberhard-Karls-Universität, Tübingen, Germany
| | - H Barthel
- Department of Nuclear Medicine, University Clinic, Leipzig, Germany
| | - A J Beer
- Department of Nuclear Medicine, Ulm University, Ulm, Germany
| | - R Botnar
- Division of Imaging Sciences and Biomedical Engineering, King's College London, London, UK
| | | | - V Goh
- Division of Imaging Sciences and Biomedical Engineering, Department of Cancer Imaging, King's College London, London, UK
| | - M Gotthardt
- Department of Nuclear Medicine, Radboud University, Nijmegen, The Netherlands
| | - R J Hicks
- Peter MacCallum Cancer Centre, Melbourne, Australia
| | - R Lanzenberger
- Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
| | - C la Fougere
- Division of Nuclear Medicine and clinical Molecular Imaging, Department of Radiology, University of Tübingen, Tübingen, Germany
| | - M Lentschig
- ZEMODI, Zentrum für Moderne Diagnostik, Bremen, Germany
| | - S G Nekolla
- Department of Nuclear Medicine, Technical University Munich, Munich, Germany
| | - T Niederdraenk
- Strategy and Innovation Technology Center, Siemens Healthcare GmbH, Erlangen, Germany
| | - K Nikolaou
- Department of Interventional and Diagnostic Radiology, Eberhard-Karls-Universität, Tübingen, Germany
| | - J Nuyts
- Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, KU Leuven - University of Leuven, Leuven, Belgium
| | - D Olego
- Philips, 3000 Minuteman Road, Andover, MA, 01810, USA
| | - K Åhlström Riklund
- Department of Diagnostic Radiology, Radiation Sciences, Umeå University/Norrlands University Hospital, Umeå, Sweden
| | - A Signore
- Nuclear Medicine Unit, Departments of Medical-Surgical Sciences and Translational Medicine, "Sapienza" University of Rome, Rome, Italy
| | - M Schäfers
- Department of Nuclear Medicine, University Hospital Münster and European Institute for Molecular Imaging, University of Münster, Münster, Germany
| | - V Sossi
- Department of Physics and Astronomy, University of British Columbia, Vancouver, Canada
| | | | - P Veit-Haibach
- Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland
| | - L Umutlu
- Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany
| | - M Wissmeyer
- Department of Nuclear Medicine, University Hospital of Geneva, Geneva, Switzerland
| | - T Beyer
- Center for Medical Physics and Biomedical Engineering, General Hospital Vienna, Medical University Vienna, 4L, Waehringer Guertel 18-20, 1090, Vienna, Austria.
| |
Collapse
|
10
|
Werner P, Rullmann M, Bresch A, Tiepolt S, Jochimsen T, Lobsien D, Schroeter ML, Sabri O, Barthel H. Impact of attenuation correction on clinical [(18)F]FDG brain PET in combined PET/MRI. EJNMMI Res 2016; 6:47. [PMID: 27255510 PMCID: PMC4891306 DOI: 10.1186/s13550-016-0200-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2016] [Accepted: 05/23/2016] [Indexed: 01/03/2023] Open
Abstract
Background In PET/MRI, linear photon attenuation coefficients for attenuation correction (AC) cannot be directly derived, and cortical bone is, so far, usually not considered. This results in an underestimation of the average PET signal in PET/MRI. Recently introduced MR-AC methods predicting bone information from anatomic MRI or proton density-weighted zero-time imaging may solve this problem in the future. However, there is an ongoing debate if the current error is acceptable for clinical use and/or research. Methods We examined this feature for [18F] fluorodeoxyglucose (FDG) brain PET in 13 patients with clinical signs of dementia or movement disorders who subsequently underwent PET/CT and PET/MRI on the same day. Multiple MR-AC approaches including a CT-derived AC were applied. Results The resulting PET data was compared to the CT-derived standard regarding the quantification error and its clinical impact. On a quantitative level, −11.9 to +2 % deviations from the CT-AC standard were found. These deviations, however, did not translate into a systematic diagnostic error. This, as overall patterns of hypometabolism (which are decisive for clinical diagnostics), remained largely unchanged. Conclusions Despite a quantitative error by the omission of bone in MR-AC, clinical quality of brain [18F]FDG is not relevantly affected. Thus, brain [18F]FDG PET can already, even now with suboptimal MR-AC, be utilized for clinical routine purposes, even though the MR-AC warrants improvement.
Collapse
Affiliation(s)
- P Werner
- Department of Nuclear Medicine, Leipzig University Hospital, Leipzig, Germany
| | - M Rullmann
- Department of Nuclear Medicine, Leipzig University Hospital, Leipzig, Germany
| | - A Bresch
- Department of Nuclear Medicine, Leipzig University Hospital, Leipzig, Germany
| | - S Tiepolt
- Department of Nuclear Medicine, Leipzig University Hospital, Leipzig, Germany
| | - T Jochimsen
- Department of Nuclear Medicine, Leipzig University Hospital, Leipzig, Germany
| | - D Lobsien
- Department of Neuroradiology, Leipzig University Hospital, Leipzig, Germany
| | - M L Schroeter
- Day Clinic for Cognitive Neurology, Leipzig University Hospital and Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany
| | - O Sabri
- Department of Nuclear Medicine, Leipzig University Hospital, Leipzig, Germany
| | - H Barthel
- Department of Nuclear Medicine, Leipzig University Hospital, Leipzig, Germany.
| |
Collapse
|
11
|
Maiwald B, Purz S, Voigt P, Barthel H, Kahn T, Sabri O, Stumpp P. Quantitativer Vergleich der ADC- und SUV-Werte bei Patienten mit neuroendokrinem Tumor im simultanen 68Ga-DOTATOC-PET/MRT. ROFO-FORTSCHR RONTG 2016. [DOI: 10.1055/s-0036-1581656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
12
|
Diogo R, Purz S, Gawlitza M, Barthel H, Boehm A, Kahn T, Sabri O, Stumpp P. 18F-FDG-PET/CT und 18F-FDG-PET/MRT zur Diagnostik von HNO-Rezidivtumoren im Vergleich. ROFO-FORTSCHR RONTG 2016. [DOI: 10.1055/s-0036-1581591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
13
|
Bailey DL, Antoch G, Bartenstein P, Barthel H, Beer AJ, Bisdas S, Bluemke DA, Boellaard R, Claussen CD, Franzius C, Hacker M, Hricak H, la Fougère C, Gückel B, Nekolla SG, Pichler BJ, Purz S, Quick HH, Sabri O, Sattler B, Schäfer J, Schmidt H, van den Hoff J, Voss S, Weber W, Wehrl HF, Beyer T. Combined PET/MR: The Real Work Has Just Started. Summary Report of the Third International Workshop on PET/MR Imaging; February 17-21, 2014, Tübingen, Germany. Mol Imaging Biol 2016; 17:297-312. [PMID: 25672749 PMCID: PMC4422837 DOI: 10.1007/s11307-014-0818-0] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
This paper summarises the proceedings and discussions at the third annual workshop held in Tübingen, Germany, dedicated to the advancement of the technical, scientific and clinical applications of combined PET/MRI systems in humans. Two days of basic scientific and technical instructions with "hands-on" tutorials were followed by 3 days of invited presentations from active researchers in this and associated fields augmented by round-table discussions and dialogue boards with specific themes. These included the use of PET/MRI in paediatric oncology and in adult neurology, oncology and cardiology, the development of multi-parametric analyses, and efforts to standardise PET/MRI examinations to allow pooling of data for evaluating the technology. A poll taken on the final day demonstrated that over 50 % of those present felt that while PET/MRI technology underwent an inevitable slump after its much-anticipated initial launch, it was now entering a period of slow, progressive development, with new key applications emerging. In particular, researchers are focusing on exploiting the complementary nature of the physiological (PET) and biochemical (MRI/MRS) data within the morphological framework (MRI) that these devices can provide. Much of the discussion was summed up on the final day when one speaker commented on the state of PET/MRI: "the real work has just started".
Collapse
Affiliation(s)
- D L Bailey
- Department of Nuclear Medicine, Royal North Shore Hospital, and Faculty of Health Sciences, University of Sydney, Sydney, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Brandmaier P, Purz S, Bremicker K, Höckel M, Barthel H, Kluge R, Kahn T, Sabri O, Stumpp P. Simultaneous [18F]FDG-PET/MRI: Correlation of Apparent Diffusion Coefficient (ADC) and Standardized Uptake Value (SUV) in Primary and Recurrent Cervical Cancer. PLoS One 2015; 10:e0141684. [PMID: 26551527 PMCID: PMC4638340 DOI: 10.1371/journal.pone.0141684] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2015] [Accepted: 10/12/2015] [Indexed: 01/18/2023] Open
Abstract
Objectives Previous non–simultaneous PET/MR studies have shown heterogeneous results about the correlation between standardized uptake values (SUVs) and apparent diffusion coefficients (ADCs). The aim of this study was to investigate correlations in patients with primary and recurrent tumors using a simultaneous PET/MRI system which could lead to a better understanding of tumor biology and might play a role in early response assessment. Methods We included 31 patients with histologically confirmed primary (n = 14) or recurrent cervical cancer (n = 17) who underwent simultaneous whole-body 18F-FDG-PET/MRI comprising DWI. Image analysis was performed by a radiologist and a nuclear physician who identified tumor margins and quantified ADC and SUV. Pearson correlations were calculated to investigate the association between ADC and SUV. Results 92 lesions were detected. We found a significant inverse correlation between SUVmax and ADCmin (r = -0.532, p = 0.05) in primary tumors as well as in primary metastases (r = -0.362, p = 0.05) and between SUVmean and ADCmin (r = -0.403, p = 0.03). In recurrent local tumors we found correlations for SUVmax and ADCmin (r = -0.747, p = 0.002) and SUVmean and ADCmin (r = -0.773, p = 0.001). Associations for recurrent metastases were not significant (p>0.05). Conclusions Our study demonstrates the feasibility of fast and reliable measurement of SUV and ADC with simultaneous PET/MRI. In patients with cervical cancer we found significant inverse correlations for SUV and ADC which could play a major role for further tumor characterization and therapy decisions.
Collapse
Affiliation(s)
- P. Brandmaier
- Department of Diagnostic and Interventional Radiology, University Hospital Leipzig, Leipzig, Germany
- * E-mail:
| | - S. Purz
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - K. Bremicker
- Department of Diagnostic and Interventional Radiology, University Hospital Leipzig, Leipzig, Germany
| | - M. Höckel
- Department of Gynecology and Obstetrics, University Hospital Leipzig, Leipzig, Germany
| | - H. Barthel
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - R. Kluge
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - T. Kahn
- Department of Diagnostic and Interventional Radiology, University Hospital Leipzig, Leipzig, Germany
| | - O. Sabri
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - P. Stumpp
- Department of Diagnostic and Interventional Radiology, University Hospital Leipzig, Leipzig, Germany
| |
Collapse
|
15
|
Bailey DL, Pichler BJ, Gückel B, Barthel H, Beer AJ, Bremerich J, Czernin J, Drzezga A, Franzius C, Goh V, Hartenbach M, Iida H, Kjaer A, la Fougère C, Ladefoged CN, Law I, Nikolaou K, Quick HH, Sabri O, Schäfer J, Schäfers M, Wehrl HF, Beyer T. Combined PET/MRI: Multi-modality Multi-parametric Imaging Is Here: Summary Report of the 4th International Workshop on PET/MR Imaging; February 23-27, 2015, Tübingen, Germany. Mol Imaging Biol 2015; 17:595-608. [PMID: 26286794 DOI: 10.1007/s11307-015-0886-9] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
This paper summarises key themes and discussions from the 4th international workshop dedicated to the advancement of the technical, scientific and clinical applications of combined positron emission tomography (PET)/magnetic resonance imaging (MRI) systems that was held in Tübingen, Germany, from February 23 to 27, 2015. Specifically, we summarise the three days of invited presentations from active researchers in this and associated fields augmented by round table discussions and dialogue boards with specific topics. These include the use of PET/MRI in cardiovascular disease, paediatrics, oncology, neurology and multi-parametric imaging, the latter of which was suggested as a key promoting factor for the wider adoption of integrated PET/MRI. Discussions throughout the workshop and a poll taken on the final day demonstrated that attendees felt more strongly that PET/MRI has further advanced in both technical versatility and acceptance by clinical and research-driven users from the status quo of last year. Still, with only minimal evidence of progress made in exploiting the true complementary nature of the PET and MRI-based information, PET/MRI is still yet to achieve its potential. In that regard, the conclusion of last year's meeting "the real work has just started" still holds true.
Collapse
Affiliation(s)
- D L Bailey
- Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia
- Faculty of Health Sciences, University of Sydney, Sydney, Australia
| | - B J Pichler
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, Germany
| | - B Gückel
- Department of Interventional and Diagnostic Radiology, Eberhard Karls University, Tübingen, Germany
| | - H Barthel
- Department of Nuclear Medicine, Leipzig University, Leipzig, Germany
| | - A J Beer
- Department of Nuclear Medicine, Ulm University, Ulm, Germany
| | - J Bremerich
- Cardiothoracic Section, Department of Radiology and Nuclear Medicine, University of Basel Hospital, Basel, Switzerland
| | - J Czernin
- Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, USA
| | - A Drzezga
- Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany
| | - C Franzius
- Centre of Morphological and Molecular Diagnostics (ZeMoDi), MR- and PET/MRI; Centre of Nuclear Medicine and PET/CT, Bremen, Germany
| | - V Goh
- Division of Imaging Sciences and Biomedical Engineering, King's College London, London, UK
- Department of Radiology, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - M Hartenbach
- Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria
| | - H Iida
- Department of Investigative Radiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan
| | - A Kjaer
- Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
| | - C la Fougère
- Department of Nuclear Medicine and Molecular Imaging, Eberhard Karls University Tübingen, Tübingen, Germany
| | - C N Ladefoged
- Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, Denmark
| | - I Law
- Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, Denmark
| | - K Nikolaou
- Department of Interventional and Diagnostic Radiology, Eberhard Karls University, Tübingen, Germany
| | - H H Quick
- Erwin L. Hahn Institute for MR Imaging, University of Duisburg-Essen, Essen, Germany
- High Field and Hybrid MR-Imaging, University Hospital Essen, Essen, Germany
| | - O Sabri
- Department of Nuclear Medicine, Leipzig University, Leipzig, Germany
| | - J Schäfer
- Department of Interventional and Diagnostic Radiology, Eberhard Karls University, Tübingen, Germany
| | - M Schäfers
- Department of Nuclear Medicine, University Hospital Münster, Münster, Germany
| | - H F Wehrl
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, Germany
| | - T Beyer
- Center for Medical Physics and Biomedical Engineering, General Hospital Vienna, Medical University Vienna, 4L, Waehringer Guertel 18-20, 1090, Vienna, Austria.
| |
Collapse
|
16
|
Stumpp P, Maiwald B, Voigt P, Purz S, Sabri O, Barthel H, Kahn T. Simultanes 68Ga-DOTATOC-PET/MRT bei Patienten mit neuroendokrinen Tumoren:. ROFO-FORTSCHR RONTG 2015. [DOI: 10.1055/s-0035-1551331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
17
|
Werner P, Barthel H, Drzezga A, Sabri O. Current status and future role of brain PET/MRI in clinical and research settings. Eur J Nucl Med Mol Imaging 2015; 42:512-26. [PMID: 25573629 DOI: 10.1007/s00259-014-2970-9] [Citation(s) in RCA: 64] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2014] [Accepted: 12/03/2014] [Indexed: 12/11/2022]
Abstract
Hybrid PET/MRI systematically offers a complementary combination of two modalities that has often proven itself superior to the single modality approach in the diagnostic work-up of many neurological and psychiatric diseases. Emerging PET tracers, technical advances in multiparametric MRI and obvious workflow advantages may lead to a significant improvement in the diagnosis of dementia disorders, neurooncological diseases, epilepsy and neurovascular diseases using PET/MRI. Moreover, simultaneous PET/MRI is well suited to complex studies of brain function in which fast fluctuations of brain signals (e.g. related to task processing or in response to pharmacological interventions) need to be monitored on multiple levels. Initial simultaneous studies have already demonstrated that these complementary measures of brain function can provide new insights into the functional and structural organization of the brain.
Collapse
Affiliation(s)
- P Werner
- Department of Nuclear Medicine, University Hospital Leipzig, Liebigstr. 18, 04103, Leipzig, Germany
| | | | | | | |
Collapse
|
18
|
Meyer PM, Tiepolt S, Barthel H, Hesse S, Sabri O. Radioligand imaging of α4β2* nicotinic acetylcholine receptors in Alzheimer's disease and Parkinson's disease. Q J Nucl Med Mol Imaging 2014; 58:376-386. [PMID: 25387119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
The α4β2* nicotinic acetylcholine receptors (α4β2*-nAChR) are highly abundant in the human brain. As neuromodulators they play an important role in cognitive functions such as memory, learning and attention as well as mood and motor function. Post mortem studies suggest that abnormalities of α4β2*-nAChRs are closely linked to histopathological hallmarks of Alzheimer's disease (AD), such as amyloid aggregates/oligomers and tangle pathology and of Parkinson's disease (PD) such as Lewy body pathology and the nigrostriatal dopaminergic deficit. In this review we summarize and discuss nicotinic receptor imaging findings of 2-[18F]FA-85380 PET, [11C]nicotine PET and 5-[123I]IA-85380 SPECT studies investigating α4β2*-nAChR binding in vivo and their relationship to mental dysfunction in the brain of patients with AD and patients out of the spectrum of Lewy body disorders such as PD and Lewy body dementia (DLB). Furthermore, recent developments of novel α4β2*-nAChR-specific PET radioligands, such as (-)[18F]Flubatine or [18F]AZAN are summarized. We conclude that α4β2*-nAChR-specific PET might become a biomarker for early diagnostics and drug developments in patients with AD, DLB and PD, even at early or prodromal stages.
Collapse
Affiliation(s)
- P M Meyer
- Department of Nuclear Medicine University of Leipzig, Leipzig, Germany -
| | | | | | | | | |
Collapse
|
19
|
Werner P, Vilia Z, Saur D, Patt M, Sattler B, Jochimsen T, Lobsien D, Then Bergh F, Dreyer A, Boltze J, Classen J, Hoffmann KT, Sabri O, Barthel H. Etablierung der kombinierten [15O]H2O-PET/MRT am Großtiermodell und bei Patienten mit (sub)akutem Schlaganfall. KLIN NEUROPHYSIOL 2014. [DOI: 10.1055/s-0034-1371193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
20
|
Balard H, Donnet JB, Oulanti H, Gottschalk-Gaudig T, Barthel H. Study of aging of pyrogenic silicas by gravimetry and microcalorimetry. Colloids Surf A Physicochem Eng Asp 2011. [DOI: 10.1016/j.colsurfa.2011.01.040] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
21
|
Barthel H, Gertz H, Dresel S, Heuser I, Bartenstein P, Buerger K, Reininger C, Hiemeyer F, Sabri O. FP43-TH-03 [18 F]BAY 94–9172 positron emission tomography in the detection/exclusion of cerebral amyloid beta: an open-label, multicentre study in patients with probable Alzheimer's disease compared with healthy volunteers. J Neurol Sci 2009. [DOI: 10.1016/s0022-510x(09)70497-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
22
|
Günther T, Hesse S, Kendziorra K, Barthel H, Sander C, Olbrich S, Adamaszek M, Becker G, Sabri O, Hegerl U, Schönknecht P. EEG-based vigilance and cerebral glucose metabolism – a parallel EEG and FDG PET study. Pharmacopsychiatry 2009. [DOI: 10.1055/s-0029-1240122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
23
|
Schroeter ML, Vogt B, Frisch S, Becker G, Seese A, Barthel H, Scheid R, Villringer A, Sabri O. Dissociating Behavioral Disorders in Dementia - An FDG-PET Study. Neuroimage 2009. [DOI: 10.1016/s1053-8119(09)70700-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
24
|
Dukart J, Mueller K, Horstmann A, Vogt B, Barthel H, Becker G, Frisch S, Villringer A, Sabri O, Schroeter ML. Differential Effects of Global and Cerebellar Normalization on Dementia in FDG-PET Studies. Neuroimage 2009. [DOI: 10.1016/s1053-8119(09)71016-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
25
|
Hesse S, Barthel H, Strecker K, Oehlwein C, Sabri O, Schwarz J. Nuklearmedizinische Diagnostik beim Parkinson-Syndrom. Akt Neurol 2008. [DOI: 10.1055/s-2008-1067504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
26
|
Kellou H, Hamdi B, Brendlé E, Gottschalk-Gaudig T, Barthel H, Ridaoui H, Balard H, Donnet JB. Surface properties of dimethylsilylated silicas, assessed using IGC at finite concentration. Colloids Surf A Physicochem Eng Asp 2008. [DOI: 10.1016/j.colsurfa.2008.06.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
27
|
Kätzel U, Gottschalk-Gaudig T, Stintz M, Barthel H. Struktur-Eigenschaftsbeziehungen polydisperser fraktaler Stoffsysteme. CHEM-ING-TECH 2008. [DOI: 10.1002/cite.200750628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
28
|
Boltze J, Förschler A, Barthel H, Nitzsche B, Boltze C, Reischauer A, Hoffmann A, Sabri O, Emmrich F, Gille U. Reduktion von neurologischen Defiziten und Infarktgröße durch Gabe autologer Knochenmarkszellen nach experimentellem Schlaganfall im Schaf. Akt Neurol 2008. [DOI: 10.1055/s-0028-1086526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
29
|
Kätzel U, Richter T, Stintz M, Barthel H, Gottschalk-Gaudig T. Zeitinvariante und zeitabhängige Einflüsse von Partikelwechselwirkungen auf das Diffusionsverhalten in Suspensionen. CHEM-ING-TECH 2006. [DOI: 10.1002/cite.200650231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
30
|
Strecker K, Schneider JP, Barthel H, Hermann W, Wegner F, Wagner A, Schwarz J, Sabri O, Zimmer C. Profound midbrain atrophy in patients with Wilson's disease and neurological symptoms? J Neurol 2006; 253:1024-9. [PMID: 16607473 DOI: 10.1007/s00415-006-0151-x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2005] [Revised: 01/18/2006] [Accepted: 01/24/2006] [Indexed: 12/20/2022]
Abstract
Wilson's disease (WD) is characterized by impaired hepatic copper secretion and subsequent copper accumulation in many organs predominantly liver and brain, secondary to loss of function mutations in the copper transport protein ATP7B. If the disease is recognized too late or treatment is not adequate, brain copper accumulation leads to progressive neurodegeneration with a variety of clinical symptoms. The nigrostriatal dopaminergic system seems rather vulnerable. Midbrain atrophy, however, has not been recognized as one of the prime features of patients with WD. Here we report quantification of midbrain diameter in 41 patients with WD. Data were correlated to the severity of neurological symptoms and the integrity of dopaminergic neurons measured via dopamine transporter binding. For control, we measured midbrain diameter in 18 patients with no evidence for brainstem dysfunction and 5 patients with progressive supranuclear palsy (PSP). Patients with WD had a reduced midbrain diameter (15.5 +/- 0.4 mm) compared to controls (18.5 +/- 0.2 mm). WD patients without neurological symptoms had midbrain diameter that were not different from controls (18.0 +/- 0.3 mm), while patients with neurological symptoms showed midbrain atrophy similar to patients with PSP (14.4 +/- 0.3 mm versus 14.1 +/- 0.3). There was a strong and significant correlation between midbrain atrophy and the severity of neurological symptoms (r= -0.68, p < 0.001) while midbrain atrophy and dopamine transporter binding correlated significantly but was less pronounced (r=0.46, p < 0.001). In summary, we were able to show, that midbrain diameter is an easy to perform quantification of neurodegeneration induced by brain copper accumulation and that other structures than substantia nigra dopaminergic neurons seem to contribute to midbrain atrophy in WD.
Collapse
Affiliation(s)
- K Strecker
- Department of Neurology, University of Leipzig, Liebigstr.22a, 04103 Liebigstr, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Hesse S, Oehlwein C, Barthel H, Schwarz J, Polster D, Wagner A, Sabri O. Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome. J Neural Transm (Vienna) 2006; 113:1177-90. [PMID: 16463120 DOI: 10.1007/s00702-005-0401-6] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2005] [Accepted: 09/26/2005] [Indexed: 10/25/2022]
Abstract
Single-photon emission computed tomography (SPECT) markers allow measuring the integrity of the brain dopaminergic system in vivo. We used dopamine transporter (DAT) SPECT with [(123)I]FP-CIT and dopamine D(2)/D(3) receptor SPECT with [(123)I]IBZM to evaluate whether there is a reduction of DAT and/or D(2)/D(3) receptor SPECT in treated and untreated patients with Parkinsonian syndrome (PS). We found that almost a quarter of our patients treated with anti-Parkinsonian medication prior to SPECT imaging did not show evidence of a presynaptic dopaminergic deficit while 37% of untreated patients were diagnosed as having Parkinson's disease. 17% of treated patients had additional loss of D(2)/D(3) receptor binding capacity in concordance with the clinical follow-up diagnoses of multiple system atrophy, progressive nuclear palsy, and vascular Parkinsonism. Apart from 38% clinically uncertain cases, SPECT was in concordance with 75% of initial clinical diagnoses. 25% were reclassified as indicated by SPECT findings and confirmed by a 1.5-year clinical follow-up. We conclude that dopamine SPECT may support establishing or refuting the clinical diagnosis and, therefore, help to make the decision for or against dopaminomimetic treatment in cases with PS.
Collapse
Affiliation(s)
- S Hesse
- Clinic for Nuclear Medicine, University Hospital, Leipzig, Germany.
| | | | | | | | | | | | | |
Collapse
|
32
|
Kätzel U, Stintz M, Barthel H. Charakterisierung von Wechselwirkungseinflüssen auf die Partikeldiffusion mittels Photonenkorrelationsspektroskopie. CHEM-ING-TECH 2006. [DOI: 10.1002/cite.200500094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
33
|
Kendziorra K, Meyer P, Wolf H, Barthel H, Hesse S, Seese A, Sorger D, Patt M, Becker G, Schildan A, Gertz H, Sabri O. Cerebral nicotinic acetylcholine receptors in patients with Alzheimer's disease assessed with 2-[18F]F-A85380 PET—correlations to dementia severity. Neuroimage 2006. [DOI: 10.1016/j.neuroimage.2006.04.029] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
34
|
Hermann W, Günther P, Wagner A, Schneider J, Huster D, Kühn H, Reichel G, Heinze S, Sabri O, Barthel H. Einteilung des Morbus Wilson basierend auf dem Vorliegen der H1069Q-Mutation. Akt Neurol 2006. [DOI: 10.1055/s-2006-953167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
35
|
Lobsien D, Meyer P, Barthel H, Schneider J, Kahn T, Gertz HJ, Schwarz J, Sabri O, Zimmer C. Diffusion Tensor Imaging (DTI) in Korrelation zu 2-[18F]F-A-85380 PET (2-FA-PET) zur Untersuchung der weißen Substanz bei Patienten mit Morbus Alzheimer (AD) und Morbus Parkinson (PD). ROFO-FORTSCHR RONTG 2006. [DOI: 10.1055/s-2006-940776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
36
|
Kendziorra K, Meyer P, Wolf H, Hesse S, Barthel H, Becker G, Schildan A, Lobsien D, Sorger D, Seese A, Gertz H, Sabri O. Cerebral nicotinic acetylcholine receptors in the periventricular white matter in patients with Alzheimer's disease and vascular dementia—a 2-[18F]F-A85380 PET investigation. Neuroimage 2006. [DOI: 10.1016/j.neuroimage.2006.04.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
37
|
Meyer P, Hesse S, Kendziorra K, Becker G, Wegner F, Schildan A, Seese A, Lobsien D, Barthel H, Schwarz J, Sabri O. Dissociation between striatal alpha4beta2 nicotinic acetylcholine receptors (alpha4beta2) and dopamine transporters (DAT) in Parkinson disease: A 2-[18F]-F-A-85380 PET/[123I]-FP-CIT SPECT study. Neuroimage 2006. [DOI: 10.1016/j.neuroimage.2006.04.140] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
38
|
Barthel H, Kluge R, Sabri O. Stellenwert der PET in der Diagnostik des kolorektalen Karzinoms. ROFO-FORTSCHR RONTG 2005. [DOI: 10.1055/s-2005-867333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
39
|
Kendziorra K, Barthel H, Winkler D, Schober R, Zimmer C, Meixensberger J, Sabri O. Intracranial germinoma diagnosed by fluorine-18-FDG-PET-guided stereotactic biopsy. Nuklearmedizin 2004; 43:N80-3. [PMID: 15628025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Affiliation(s)
- K Kendziorra
- Clinic of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
BACKGROUND Lidocaine is frequently used as an agent to treat ventricular arrhythmias associated with acute myocardial ischaemia. Lidocaine is a potent blocker not only of sodium channels, but also of ATP-sensitive potassium channels. The opening of these channels is a key mechanism of ischaemic preconditioning. We investigated the hypothesis that lidocaine blocks the cardioprotection induced by ischaemic preconditioning. METHODS Isolated rat hearts (n=60) were subjected to 30 min of no-flow ischaemia and 60 min of reperfusion. Control hearts (CON) underwent no further intervention. Preconditioned hearts (PC) received two 5-min periods of ischaemia separated by 10 min of reflow before the 30 min ischaemia. In three groups, lidocaine was infused at concentrations of 2, 10 or 20 microg ml(-1) for 5 min before the preconditioning ischaemia. Left ventricular developed pressure (LVDP) and infarct size (IS) (triphenyltetrazolium choride staining) were measured as variables of ventricular function and cellular injury, respectively. RESULTS PC reduced IS from 24.8 (sem 4.1) % to 4.0 (0.7) % of the area at risk (P<0.05). Adding 2 or 10 microg ml(-1) lidocaine had no effect on IS compared with PC alone (3.7 (0.7) %, 6.9 (1.8) %). Adding 20 microg ml(-1) lidocaine increased IS to 14.1 (2.5) % compared with PC (P<0.05). Baseline LVDP was similar in all groups (111.4 (2.1) mm Hg). Compared with CON, PC improved functional recovery (after 60 min of reperfusion; 52.3 (5.9) mm Hg vs 16.0 (4.0) mm Hg, P<0.01). The improved ventricular function was not influenced by addition of 2 or 10 microg ml(-1) lidocaine (47.3 (5.7) mm Hg, not significant; 45.3 (7.3) mm Hg, not significant), but was blocked by the infusion of 20 microg ml(-1) lidocaine (22.5 (8.0) mm Hg, P<0.01 vs PC). CONCLUSIONS Lidocaine blocks the cardioprotection induced by ischaemic preconditioning only at supratherapeutic concentrations.
Collapse
Affiliation(s)
- H Barthel
- Klinik für Anaesthesiologie, Universitätklinikum Düsseldorf, Postfach 10 10 07, D-40001 Düsseldorf, Germany
| | | | | | | | | | | |
Collapse
|
41
|
Barthel H, Wilson H, Collingridge DR, Brown G, Osman S, Luthra SK, Brady F, Workman P, Price PM, Aboagye EO. In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br J Cancer 2004; 90:2232-42. [PMID: 15150578 PMCID: PMC2409496 DOI: 10.1038/sj.bjc.6601862] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Development of hypoxia-targeted therapies has stimulated the search for clinically applicable noninvasive markers of tumour hypoxia. Here, we describe the validation of [18F]fluoroetanidazole ([18F]FETA) as a tumour hypoxia marker by positron emission tomography (PET). Cellular transport and retention of [18F]FETA were determined in vitro under air vs nitrogen. Biodistribution and metabolism of the radiotracer were determined in mice bearing MCF-7, RIF-1, EMT6, HT1080/26.6, and HT1080/1-3C xenografts. Dynamic PET imaging was performed on a dedicated small animal scanner. [18F]FETA, with an octanol–water partition coefficient of 0.16±0.01, was selectively retained by RIF-1 cells under hypoxia compared to air (3.4- to 4.3-fold at 60–120 min). The radiotracer was stable in the plasma and distributed well to all the tissues studied. The 60-min tumour/muscle ratios positively correlated with the percentage of pO2 values <5 mmHg (r=0.805, P=0.027) and carbogen breathing decreased [18F]FETA-derived radioactivity levels (P=0.028). In contrast, nitroreductase activity did not influence accumulation. Tumours were sufficiently visualised by PET imaging within 30–60 min. Higher fractional retention of [18F]FETA in HT1080/1-3C vs HT1080/26.6 tumours determined by dynamic PET imaging (P=0.05) reflected higher percentage of pO2 values <1 mmHg (P=0.023), lower vessel density (P=0.026), and higher radiobiological hypoxic fraction (P=0.008) of the HT1080/1-3C tumours. In conclusion, [18F]FETA shows hypoxia-dependent tumour retention and is, thus, a promising PET marker that warrants clinical evaluation.
Collapse
Affiliation(s)
- H Barthel
- Cancer Research UK PET Oncology Group, Department of Cancer Medicine, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, W12 0NN London, UK
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 20A, 04103 Leipzig, Germany
| | - H Wilson
- Hammersmith Imanet, Cyclotron Building, Hammersmith Hospital, Du Cane Road, W12 0NN London, UK
| | - D R Collingridge
- Cancer Research UK PET Oncology Group, Department of Cancer Medicine, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, W12 0NN London, UK
| | - G Brown
- Hammersmith Imanet, Cyclotron Building, Hammersmith Hospital, Du Cane Road, W12 0NN London, UK
| | - S Osman
- Hammersmith Imanet, Cyclotron Building, Hammersmith Hospital, Du Cane Road, W12 0NN London, UK
| | - S K Luthra
- Hammersmith Imanet, Cyclotron Building, Hammersmith Hospital, Du Cane Road, W12 0NN London, UK
| | - F Brady
- Hammersmith Imanet, Cyclotron Building, Hammersmith Hospital, Du Cane Road, W12 0NN London, UK
| | - P Workman
- Cancer Research UK Centre for Cancer Therapeutics, The Institute for Cancer Research, Brookes Lawley Building, Room 0E8, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - P M Price
- Cancer Research UK PET Oncology Group, Department of Cancer Medicine, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, W12 0NN London, UK
| | - E O Aboagye
- Cancer Research UK PET Oncology Group, Department of Cancer Medicine, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, W12 0NN London, UK
- Molecular Therapy Group, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK. E-mail:
| |
Collapse
|
42
|
Banning U, Barthel H, Kluge R, Körholz D, Sabri O. [18F]fluorodeoxyglucose (FDG) in vitro uptake in Hodgkin Lymphoma. Klin Padiatr 2004. [DOI: 10.1055/s-2004-828549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
43
|
Collingridge DR, Glaser M, Osman S, Barthel H, Hutchinson OC, Luthra SK, Brady F, Bouchier-Hayes L, Martin SJ, Workman P, Price P, Aboagye EO. In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope. Br J Cancer 2003; 89:1327-33. [PMID: 14520468 PMCID: PMC2394302 DOI: 10.1038/sj.bjc.6601262] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
The availability of a noninvasive method to detect and quantify apoptosis in tumours will enable tumour response to several cancer therapies to be assessed. We have synthesised two radiotracers, annexin V and the N-succinimidyl-3-iodobenzoic acid (SIB) derivative of annexin V, labelled with radio-iodine (124I and 125I) and provided proof of the concept by assessing specific binding and biodistribution of these probes to apoptotic cells and tumours. We have also assessed the tumour uptake of [124I]annexin V in a mouse model of apoptosis. RIF-1 cells induced to undergo apoptosis in vitro showed a drug concentration-dependent increased binding of [125I]annexin V and [125I]SIB–annexin V. In the same model system, there was an increase in terminal deoxynucleotidyl transferase-mediated nick end labelling (TUNEL)-positive cells and a decrease in clonogenic survival. Radiotracer binding was completely inhibited by preincubation with unlabelled annexin V. In RIF-1 tumour-bearing mice, rapid distribution of [125I]SIB–annexin V-derived radioactivity to kidneys was observed and the radiotracer accumulated in urine. The binding of [125I]SIB–annexin V to RIF-1 tumours increased by 2.3-fold at 48 h after a single intraperitoneal injection of 5-fluorouracil (165 mg kg−1 body weight), compared to a 4.4-fold increase in TUNEL-positive cells measured by immunostaining. Positron emission tomography images with both radiotracers demonstrated intense localisation in the kidneys and bladder. Unlike [124I]SIB–annexin V, [124I]annexin V also showed localisation in the thyroid region presumably due to deiodination of the radiolabel. [124I]SIB–annexin V is an attractive candidate for in vivo imaging of apoptosis by PET.
Collapse
Affiliation(s)
- D R Collingridge
- Cancer Research UK PET Oncology Group, Department of Cancer Medicine, Imperial College of Science Technology and Medicine, MRC Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
| | - M Glaser
- Imaging Research Solutions Limited, MRC Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
| | - S Osman
- Imaging Research Solutions Limited, MRC Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
| | - H Barthel
- Cancer Research UK PET Oncology Group, Department of Cancer Medicine, Imperial College of Science Technology and Medicine, MRC Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
- Department of Nuclear Medicine, University of Leipzig, Liebigstrasse 20A, 04103 Leipzig, Germany
| | - O C Hutchinson
- Cancer Research UK PET Oncology Group, Department of Cancer Medicine, Imperial College of Science Technology and Medicine, MRC Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
| | - S K Luthra
- Imaging Research Solutions Limited, MRC Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
| | - F Brady
- Imaging Research Solutions Limited, MRC Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
| | - L Bouchier-Hayes
- The Smurfit Institute of Genetics, Trinity College, Dublin, Ireland
| | - S J Martin
- The Smurfit Institute of Genetics, Trinity College, Dublin, Ireland
| | - P Workman
- Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey SM2 SNG, UK
| | - P Price
- Cancer Research UK PET Oncology Group, Department of Cancer Medicine, Imperial College of Science Technology and Medicine, MRC Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
| | - E O Aboagye
- Cancer Research UK PET Oncology Group, Department of Cancer Medicine, Imperial College of Science Technology and Medicine, MRC Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
- Cancer Research UK PET Oncology Group, Department of Cancer Medicine, Imperial College of Science Technology and Medicine, MRC Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK. E-mail:
| |
Collapse
|
44
|
Hesse S, Barthel H, Hermann W, Murai T, Kluge R, Wagner A, Sabri O, Eggers B. Regional serotonin transporter availability and depression are correlated in Wilson's disease. J Neural Transm (Vienna) 2003; 110:923-33. [PMID: 12898347 DOI: 10.1007/s00702-003-0008-8] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
In patients with Wilson's disease (WD), depression is a frequent psychiatric symptom. In vivo neuroimaging studies suggest that depression and other neuropsychiatric disorders are associated with central serotonergic deficits. However, in vivo measurements of serotonergic neurotransmission have not until now been performed in patients with this copper deposition disorder. The present prospective study revealed that depressive symptomatology is related to an alteration of presynaptic serotonin transporters (SERT) availability as measured by [123I]-2beta-carbomethoxy-3beta-(iodophenyl)tropane ([123I]beta-CIT) and high-resolution single-photon emission computed tomography (SPECT). SERT imaging with [123I]beta-CIT-SPECT could therefore become a useful tool for diagnosis and therapy monitoring in depressed WD patients.
Collapse
Affiliation(s)
- S Hesse
- Clinic for Nuclear Medicine, University Hospital, University of Leipzig, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Wang M, Bertmer M, Demco DE, Blümich B, Litvinov VM, Barthel H. Indication of Heterogeneity in Chain-Segment Order of a PDMS Layer Grafted onto a Silica Surface by 1H Multiple-Quantum NMR. Macromolecules 2003. [DOI: 10.1021/ma0217534] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Mingfei Wang
- Institut für Technische Chemie und Makromolekulare Chemie, Rheinisch-Westfälische Technische Hochschule, Worringerweg 1, D-52056 Aachen, Germany; DSM Research, P.O. Box 18, 6160 MD Geelen, The Netherlands; and Wacker-Chemie GmbH, Werk Burghausen, D-84480 Burghausen, Germany
| | - M. Bertmer
- Institut für Technische Chemie und Makromolekulare Chemie, Rheinisch-Westfälische Technische Hochschule, Worringerweg 1, D-52056 Aachen, Germany; DSM Research, P.O. Box 18, 6160 MD Geelen, The Netherlands; and Wacker-Chemie GmbH, Werk Burghausen, D-84480 Burghausen, Germany
| | - D. E. Demco
- Institut für Technische Chemie und Makromolekulare Chemie, Rheinisch-Westfälische Technische Hochschule, Worringerweg 1, D-52056 Aachen, Germany; DSM Research, P.O. Box 18, 6160 MD Geelen, The Netherlands; and Wacker-Chemie GmbH, Werk Burghausen, D-84480 Burghausen, Germany
| | - B. Blümich
- Institut für Technische Chemie und Makromolekulare Chemie, Rheinisch-Westfälische Technische Hochschule, Worringerweg 1, D-52056 Aachen, Germany; DSM Research, P.O. Box 18, 6160 MD Geelen, The Netherlands; and Wacker-Chemie GmbH, Werk Burghausen, D-84480 Burghausen, Germany
| | - V. M. Litvinov
- Institut für Technische Chemie und Makromolekulare Chemie, Rheinisch-Westfälische Technische Hochschule, Worringerweg 1, D-52056 Aachen, Germany; DSM Research, P.O. Box 18, 6160 MD Geelen, The Netherlands; and Wacker-Chemie GmbH, Werk Burghausen, D-84480 Burghausen, Germany
| | - H. Barthel
- Institut für Technische Chemie und Makromolekulare Chemie, Rheinisch-Westfälische Technische Hochschule, Worringerweg 1, D-52056 Aachen, Germany; DSM Research, P.O. Box 18, 6160 MD Geelen, The Netherlands; and Wacker-Chemie GmbH, Werk Burghausen, D-84480 Burghausen, Germany
| |
Collapse
|
46
|
Eggers B, Hermann W, Barthel H, Sabri O, Wagner A, Hesse S. The degree of depression in Hamilton rating scale is correlated with the density of presynaptic serotonin transporters in 23 patients with Wilson's disease. J Neurol 2003; 250:576-80. [PMID: 12736737 DOI: 10.1007/s00415-003-1039-7] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
OBJECTIVE One of the most frequent psychiatric symptoms in patients with Wilson's disease (WD) is depression. It has been suggested that depression is associated with deficits in serotonergic neurotransmission, but, hitherto, no measurements have been performed in WD. METHODS We prospectively examined 23 adult patients (12 women, 11 men, mean age 40 years) with WD for symptoms of depression using the Hamilton rating scale for depression (HAMD). We correlated the data with the presynaptic serotonin transporter density (SERT density) in the thalamus-hypothalamus and the midbrain-pons regions measured with high resolution single-photon emission computed tomography (SPECT) 24 hours after the application of 180 MBq 2beta-carbomethoxy-3beta-(4 [(123)I]iodophenyl)tropane ( [(123)I]b-CIT). The regions of interest were determined by coregistration with a standard MRI dataset. RESULTS A significant negative correlation was found between HAMD and SERT density in the thalamus-hypothalamus region (r = -0.49, p = 0.02), but not in the midbrain-pons (r = -0.31, p = 0.15). CONCLUSIONS We conclude that depression in patients with Wilson's disease is correlated with alterations of serotonergic neurotransmission in the thalamus-hypothalamus region.
Collapse
Affiliation(s)
- B Eggers
- Department of Neurology, University of Leipzig, Liebigstr. 22a, 04103 Leipzig, Germany
| | | | | | | | | | | |
Collapse
|
47
|
Hamdi S, Hamdi B, Kessaissia Z, Barthel H, Balard H, Donnet JB. Influence of poly(methyl methacrylate) impregnation ratio on the surface properties of fumed silica and on the glassy temperature of poly(methyl methacrylate) using inverse gas chromatographic analysis. J Chromatogr A 2002; 969:143-51. [PMID: 12385387 DOI: 10.1016/s0021-9673(02)00897-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The surface properties of poly(methyl methacrylate) (PMMA) impregnated fumed silicas, in a large range of impregnation ratios, were examined using inverse gas chromatography at infinite dilution. It was observed that the dispersive component gamma(s)d does not decrease monotonously with the impregnation ratio. Two critical coverage ratios were evidenced corresponding at first to the shielding of the most energetic sites and then to the achievement of total coverage of the silica surface. The influence of the coverage ratio on the glassy temperature (tg) of the adsorbed PMMA was also studied, which was evidenced down to a very low coverage ratio (1 monomer unit/nm2).
Collapse
Affiliation(s)
- S Hamdi
- L.E.P.C.M.A.E., Faculté de Chimie, USTHB10, Alger, Algeria
| | | | | | | | | | | |
Collapse
|
48
|
Barthel H, Nikitina E. INS and IR study of intermolecular interactions at the fumed silica-polydimethylsiloxane interphase, Part 2. Hydrophillic and silylated silica components. ACTA ACUST UNITED AC 2002. [DOI: 10.1023/b:silc.0000018352.82212.c8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
49
|
Hermann W, Barthel H, Hesse S, Grahmann F, Kühn HJ, Wagner A, Villmann T. Comparison of clinical types of Wilson's disease and glucose metabolism in extrapyramidal motor brain regions. J Neurol 2002; 249:896-901. [PMID: 12140675 DOI: 10.1007/s00415-002-0756-7] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
In Wilson's disease a disturbed glucose metabolism especially in striatal and cerebellar areas has been reported. This is correlated with the severity of extrapyramidal motor symptoms (EPS). These findings are only based on a small number of patients. Up to now it is unknown whether EPS are caused by various patterns of disturbed basal ganglia glucose metabolism. We investigated 37 patients and 9 normal volunteers to characterize the disturbed glucose metabolism in Wilson's disease more precisely. The glucose metabolism was determined in 5 cerebellar and cerebral areas (putamen, caput nuclei caudati, cerebellum, midbrain and thalamic area) by using (18)F-Fluorodesoxyglucose-Positron-Emission-Tomography ( [(18)F]FDG-PET). The database was evaluated by a cluster analysis. Additionally, the severity extrapyramidal motor symptoms were judged by a clinical score system. Three characteristic patterns of glucose metabolism in basal ganglia were obtained. Two of them may be assigned to patients with neurological symptoms whereas the third cluster corresponds to most patients without EPS or normal volunteers. The clusters can be identified by characteristic consumption rates in this 5 brain areas. The severity of EPS can not clearly be assigned to one of the clusters with disturbed glucose metabolism. However, the most severe cases are characterized by the lowest consumption in the striatal area. When there is marked improvement of EPS impaired glucose consumption reveals a persistent brain lesion. Finally, the neurological symptoms in Wilson's disease are caused by (at least) two different patterns of disturbed glucose metabolism in basal ganglia and cerebellum. The severity of EPS seems to be determined by a disturbed consumption in the striatal area.
Collapse
Affiliation(s)
- W Hermann
- Clinic of Neurology, University Leipzig, Liebigstr. 22a, Germany
| | | | | | | | | | | | | |
Collapse
|
50
|
Barthel H, Nikitina E. INS and IR study of intermolecular interactions at the fumed silica-polydimethylsiloxane interphase, Part I. Polydimethylsiloxane models. ACTA ACUST UNITED AC 2002. [DOI: 10.1023/b:silc.0000018351.78847.f7] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|